InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Discover the detailed record of transactions filed by Reich Siegfried, Vice-Président Exécutif. Director active across 1 companies, notably Turning Point Therapeutics, Inc.. Aggregated, 2 reports have been published. Total volume traded: €25k. The latest transaction was filed on 9 February 2022 — Cession. Regulator: SEC (Form 4). All data is free.
Declarations2 total
€12,618397 shares@ €31.7828100.0% of flow
Common Stock
SEC:0001209191-22-008984·
€12,618397 shares@ €31.782850.0% of flow
Common Stock
SEC:0001209191-22-008984:0·
2 of 2 declarations
About Reich Siegfried
Reich Siegfried is Executive Vice President and Chief Scientific Officer at Turning Point Therapeutics, Inc. In this role, he oversees the company's research and development initiatives focused on innovation in oncology treatments. His scientific expertise and strategic vision are essential for the company's success. Reich is committed to advancing Turning Point's mission by developing targeted therapies for patients.
